NASDAQ:CALC

CalciMedica Q4 2025 Earnings Results & Report

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica reported Q4 2025 earnings on March 3, 2026. The company reported EPS of -$3.45.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

CalciMedica EPS Results

Actual EPS
-$3.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CalciMedica Q4 2025 Earnings FAQ

CalciMedica (NASDAQ:CALC) reported earnings of -$3.45 per share for Q4 2025. The report was announced on Tuesday, March 3, 2026.

CalciMedica Earnings Headlines

FY2026 EPS Estimates for CalciMedica Raised by HC Wainwright
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
CalciMedica (CALC) Set to Release Earnings on Wednesday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation.

The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.

View CalciMedica Profile